Sumeet Dhillon - ROP Study Published by American Journal of Clinical Oncology

When Sumeet Dhillon started her ROP with Dr. Jayson Parker she didn't even imagine that it will end with a first authored paper in the prestigious American Journal of Clinical Oncology.

The Effect of Biomarkers on Clinical Trial Risk in Gastric Cancer

Question:  How can we increase the success rate of new drugs during clinical trial testing for gastric cancer?

Context:  Drug development carries a failure rate during clinical testing in excess of 90%.  We need to do a better job identifying the right patient groups for the right kind of therapeutic intervention.

Methods:  We screened clinical trials over a 20 year period using the National Institute of Health publicly available database and generated risk estimates.

Results:  We found that drugs showed higher success rates with biomarker use.  In addition, drugs that are large organic molecules, typically antibodies, were superior to small molecule drugs in terms of testing success rates.  

So What?  These findings give physicians new indicators to look for in selecting clinical trials for their gastric cancer patients to participate in, that have a better chance of success.

Dhillon, Sumeet BSc*; Lopes, Gilberto MD†; Parker, Jayson L. MBA, PhD*. The Effect of Biomarkers on Clinical Trial Risk in Gastric Cancer. American Journal of Clinical Oncology: December 1, 2022 - Volume - Issue - 10.1097/COC.0000000000000963
doi: 10.1097/COC.0000000000000963